RTA NEWSLETTER - SEPTEMBER 2025
Revision of the Epidemics Act (rev EpidA): The RTA noticed with great relief and appreciation that in its message about the rev EpidA the Federal Council included complementary “twin” articles 50a and 51a lowering barriers to antibiotic research and development and enhancing the market framework to incentivize more antibiotics to be launched on the Swiss market.
Visit of Sandoz' fully integrated penicillin manufacturing site in Kundl/Austria: With 90% of all amoxicillin used in Switzerland sourced from the Kundl site, several members of the RTA seized the unique opportunity of getting first-hand insight into what it takes for a European manufacturer of penicillins to stand firm against the strong Asian competitors and impacts of Russia’s war in the Ukraine.
Compliance with Good Distribution Practices and antimicrobial stewardship in Eastern Ethiopian health care institutions: This study was funded by the Däster Schild Foundation and greatly facilitated by the Swiss TPH, the University of Lausanne (UniL) and the University of Jigjiga by providing local infrastructure, expertise and data collection capacity.
